TY  - JOUR
AU  - Krüger, Dennis M
AU  - Pena Centeno, Tonatiuh
AU  - Liu, Shiwei
AU  - Park, Tamina
AU  - Kaurani, Lalit
AU  - Pradhan, Ranjit
AU  - Huang, Yen-Ning
AU  - Risacher, Shannon L
AU  - Burkhardt, Susanne
AU  - Schütz, Anna-Lena
AU  - Wan, Yang
AU  - Shaw, Leslie M
AU  - Brodsky, Alexander S
AU  - DeStefano, Anita L
AU  - Lin, Honghuang
AU  - Schroeder, Robert
AU  - Krunic, Andre
AU  - Hempel, Nina
AU  - Sananbenesi, Farahnaz
AU  - Blusztajn, Jan Krzysztof
AU  - Saykin, Andrew J
AU  - Delalle, Ivana
AU  - Nho, Kwangsik
AU  - Fischer, Andre
TI  - The plasma miRNAome in ADNI: Signatures to aid the detection of at-risk individuals.
JO  - Alzheimer's and dementia
VL  - 20
IS  - 11
SN  - 1552-5260
CY  - Hoboken, NJ
PB  - Wiley
M1  - DZNE-2024-01342
SP  - 7479 - 7494
PY  - 2024
AB  - MicroRNAs are short non-coding RNAs that control proteostasis at the systems level and are emerging as potential prognostic and diagnostic biomarkers for Alzheimer's disease (AD).We performed small RNA sequencing on plasma samples from 847 Alzheimer's Disease Neuroimaging Initiative (ADNI) participants.We identified microRNA signatures that correlate with AD diagnoses and help predict the conversion from mild cognitive impairment (MCI) to AD.Our data demonstrate that plasma microRNA signatures can be used to not only diagnose MCI, but also, critically, predict the conversion from MCI to AD. Moreover, combined with neuropsychological testing, plasma microRNAome evaluation helps predict MCI to AD conversion. These findings are of considerable public interest because they provide a path toward reducing indiscriminate utilization of costly and invasive testing by defining the at-risk segment of the aging population.We provide the first analysis of the plasma microRNAome for the ADNI study. The levels of several microRNAs can be used as biomarkers for the prediction of conversion from MCI to AD. Adding the evaluation of plasma microRNA levels to neuropsychological testing in a clinical setting increases the accuracy of MCI to AD conversion prediction.
KW  - Humans
KW  - Alzheimer Disease: blood
KW  - Alzheimer Disease: genetics
KW  - Alzheimer Disease: diagnosis
KW  - MicroRNAs: blood
KW  - MicroRNAs: genetics
KW  - Cognitive Dysfunction: blood
KW  - Cognitive Dysfunction: genetics
KW  - Cognitive Dysfunction: diagnosis
KW  - Aged
KW  - Female
KW  - Male
KW  - Biomarkers: blood
KW  - Neuropsychological Tests: statistics & numerical data
KW  - Disease Progression
KW  - Aged, 80 and over
KW  - Neuroimaging
KW  - Alzheimer's disease (Other)
KW  - blood biomarker (Other)
KW  - cognitive decline (Other)
KW  - microRNA (Other)
KW  - mild cognitive impairment (Other)
KW  - plasma (Other)
KW  - small non‐coding RNA (Other)
KW  - MicroRNAs (NLM Chemicals)
KW  - Biomarkers (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:39291752
C2  - pmc:PMC11567822
DO  - DOI:10.1002/alz.14157
UR  - https://pub.dzne.de/record/272963
ER  -